4/A: Aspira Women's Health Director John Ragard Reports Stock Transactions

Director John Ragard of Aspira Women's Health Inc. reports the vesting and conversion of restricted stock units into common stock, along with a correction to a previous filing.

Summary

• John Ragard, a director at Aspira Women's Health Inc., reported a transaction involving restricted stock units (RSUs).
• On September 30, 2024, 4,844 RSUs vested and were converted into common stock.
• These RSUs were part of a grant of 19,375 RSUs awarded on August 22, 2024.
• The conversion of the vested RSUs resulted in the director acquiring 4,844 shares of common stock.
• This report is an amendment to a previous filing to correct the transaction type from acquired to disposed for the derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock transactions by a company director. It is neither positive nor negative, but rather a standard reporting requirement. The correction of the previous filing is a minor issue.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions in their company's stock. It provides transparency into insider trading activity.

Comparison to Industry Standards

• The reporting of stock transactions by directors is a standard practice across all publicly traded companies.
• The vesting of RSUs is a common form of equity compensation for executives and directors.
• The filing of Form 4 with the SEC is a mandatory requirement for reporting such transactions.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of outstanding shares by 4,844.
• The transaction is a standard part of executive compensation and does not have a significant impact on other stakeholders.

Key Dates

Keywords

Aspira Women's Health, John Ragard, restricted stock units, RSU, stock transaction, director, SEC Form 4, vesting, common stock